http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Park, Sae-Gwang,Jung, Young-Joo,Lee, Young-Yi,Yang, Cheul-Min,Kim, Ik-Jung,Chung, Jun-Ho,Kim, Ik-Sang,Lee, Youn-Jae,Park, Sung-Jae,Lee, Jeong-Nyeo,Seo, Su-Kil,Park, Yong-Hong,Choi, In-Hak MARY ANN LIEBERT INC PUBL 2006 VIRAL IMMUNOLOGY Vol.19 No.1
<P>CDR3 of the heavy-chain variable region of immunoglobulin is a region in which somatic mutation occurs heavily after secondary antibody response, resulting in an affinity maturation of antibodies in vivo. The aim of this study was to improve the affinity of a human single-chain variable fragment (scFv) specific for pre-S1 of hepatitis B virus (HBV) by introducing random mutagenesis in CDR3 variable region of heavy chain (V(H)) of the parental scFv clone 1E4. By using a BIAcore for panning and screening, we have selected three clones (A9, B2, and B9) with lower highest affinity (K(D)) than 1E4. Affinities of selected clones ranged from 1.7 x 10(7) mol/L to 6.3 x 10(8) mol/L, which were increased by factors of 1.4 to 4.0, respectively, compared to the parental clone. Binding inhibition assay using flow cytometry and polymerase chain reaction revealed that B2 (6.4 x 10(8) mol/L) had a higher neutralizing activity against pre-S1 or HBV virion binding to liver cell line. This anti-pre-S1 scFv can be considered as a potential therapeutic tool for a passive immunotherapy for HBV infection.</P>
Park, Jin-Hee,Kim, Hyoung Kyu,Jung, Hana,Kim, Ki Hyang,Kang, Mi Seon,Hong, Jun Hyuk,Yu, Byeng Chul,Park, Sungjae,Seo, Su-Kil,Choi, Il Whan,Kim, Soon Ha,Kim, Nari,Han, Jin,Park, Sae Gwang Spandidos Publications 2017 International journal of oncology Vol.50 No.1
<P>A major goal of breast cancer research is to prevent the molecular events that lead to tumour metastasis. It is well-established that both cytoplasmic and mitochondrial reactive oxygen species (ROS) play important roles in cell migration and metastasis. Accordingly, this study examined the molecular mechanisms of the anti-metastatic effects of NecroX-5, a mitochondrial ROS scavenger. NecroX-5 inhibited lung cancer metastasis by ameliorating migration in a mouse model. In human cancer cells, the inhibition of migration by NecroX-5 is cell type-dependent. We observed that the effect of NecroX-5 correlated with a reduction in mitochondrial ROS, but mitochondrial ROS reduction by MitoQ did not inhibit cell migration. NecroX-5 decreased intracellular calcium concentration by blocking Ca2+ influx, which mediated the inhibition of cell migration, AKT down regulation and the reduction of mitochondrial ROS levels. However, the reduction of mitochondrial ROS was not associated with supressed migration and AKT downregulation. Our study demonstrates the potential of NecroX-5 as an inhibitor of breast cancer metastasis.</P>
PARK, GA BIN,KIM, DAEJIN,PARK, SUNG JAE,LEE, HYUN-KYUNG,KIM, JI HYUN,KIM, YEONG SEOK,PARK, SAE-GWANG,CHOI, IN-HAK,YOON, SUNG HO,LEE, YOUN JAE,PAENG, SUNGHWA,HUR, DAE YOUNG UNKNOWN 2015 INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE Vol.36 No.6
<P>Hepatitis C virus (HCV) E2 protein binds to CD81, which is a component of the B cell co-stimulatory complex. The E2-CD81 interaction leads to B cell proliferation, protein tyrosine phosphorylation and to the hypermutation of immunoglobulin genes. Epidemiological studies have reported a high prevalence of B cell non-Hodgkin lymphoma (NHL) in HCV-positive patients, suggesting a potential association between HCV and Epstein-Barr virus (EBV) in the genesis of B lymphocyte proliferative disorders. In the present study, in order to investigate the association between EBV and HCV in B cells, we created an <I>in vitro</I> EBV-induced B cell transformation model. CD81 was gradually overexpressed during transformation by EBV. B cells isolated from HCV-positive patients grew more rapidly and clumped together earlier than B cells isolated from healthy donors following EBV infection. Pre-stimulation of CD81 expressed by resting B cells with anti-CD81 monoclonal antibody (mAb) or HCV E2 accelerated the generation of lymphoblastoid cell lines (LCLs) by EBV infection. These cells proliferated prominently through the early expression of interleukin-10 and intracellular latent membrane protein (LMP)-l. By contrast, the overexpression of CD81 on EBV-transformed B cells by anti-CD81 mAb or HCV E2 protein induced apoptosis through reactive oxygen species (ROS)-mediated mitochondrial dysfunction. These results suggest that the engagement of CD81 expressed by B cells has differential effects on B cell fate (proliferation or apoptosis) according to EBV infection and the expression level of CD81.</P>
Antibody Phage Display 기법과 그 응용
박세광 인제대학교 백병원 2002 仁濟醫學 Vol.23 No.2
In recent years, the use of display vectors and in vitro selection technologies has transformed the way in which we generate ligands, such as antibodies and peptides, for a given target. Using this technology, we are now able to design repertoires of ligands from scratch and use the power of phage selection to select those ligands having the desired (biological) properties. With phage display, tailor-made antibodies may be synthesized and selected to acquire the desired affinity of binding and specificity for in vitro and in vivo diagnosis, or for immunotherapy of human disease. This review addresses recent progress in the construction of, and selection from phage antibody libraries, together with novel approaches for screening phage antibodies. As the quality of large na ve and synthetic antibody repertoires improves and libraries becomes more generally available, new and exciting applications are pioneered such as the identification of novel antigens using differential selection and the generation of receptor a(nta)gonists. A combination of the design and generation of millions to billions of different ligands, together with phage display for the isolation of binding ligands and with functional assays for identifying (and possibly selecting) bio-active ligands, will open even more challenging applications of this inspiring technology, and provide a powerful tool for drug and target discovery well into the next decade.
박인철,박세광,한 진,최병선,김희덕 大韓應急醫學會 1999 대한응급의학회지 Vol.10 No.1
Background : Scuba diving has become increasingly popular in Korea. Medical problems are common with dives, especially decompression sickness(DCS). This study was performed to obtain an useful information of hyperbaric oxygen therapy in DCS in Korea. Method : We reviewed the 62 cases of Korean divers, who were diagnosed as DCS and received recompression therapy according to U, S. Navy Standard Recompression Treatment Table at Ocean and Underwater Medical Research and Training Center of ROK Navy, for 6 years Jan. 1993 to Nov. 1998. Result : 1) The mean no-decompression limit excess time between type I DCS group(72.7 min) and type Ⅱ DCS group(92.8 min) showed significant difference. 2) The rate of symptoms appeared on surfacing and within 10min. after surfacing of type Ⅰ and type Ⅱ DCS were 41.4% and 72.7%, respectively 3) The cure rate of type Ⅰ and type Ⅱ DCS were 75.9% and 42.4%, respectively. In type Ⅱ DCS group, the cure rate of the group within 12 hour-delayed recompression treatment and the group above 12 hours-delayed treatment were 64.3% and time 26.3%, respectively, and in type Ⅰ DCS group, 100% and 66.7%, respectively. Conclusion : These findings suggest that the education of safety, the strict observance of the standard decompression table, and the avoidance of excessive repeated diving are important for reducing the risk of diving related disease. And to offer proper management of DCS, there should be more multiplace hyperbaric oxygen chambers, the suitable transport system, and the specialist of diving medicine or hyperbaric medicine in Korea.